Compare Devon Energy Corp (DVN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Viatris Inc — how do they compare? Devon Energy Corp trades at $48.89 (market cap $53.81B), while Viatris Inc trades at $17.2 (market cap $20.03B). The key difference: Devon Energy Corp is far larger — about 2.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Viatris Inc for 57 Days on average.
| DVN | VTRS | |
|---|---|---|
Market Cap | $53.81B | $20.03B |
Volume | 11,556,740 | 14,109,977 |
Sector | Energy | Health |
52-Week High | $52.07 | $18.27 |
52-Week Low | $31.74 | $9.74 |
Typical Hold Time | 136 Days | 57 Days |
Enterprise Value | $64.55B | $32.15B |
Dividend Yield | 2.62% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $47.88, down 0.29% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $62.40 implying significant upside. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss, while fundamentals show solid profitability with a 16.67% net income margin and attractive valuation multiples. Activist investor pressure for strategic alternatives, including a potential sale, has been a key recent development.
The outlook is positive, supported by strong analyst buy ratings (71.87%) and projected revenue growth to $19.7B in 2026. Key risks include oil price volatility, execution of asset sales, and rising debt levels, but the current valuation and cash flow generation present a compelling opportunity for value-oriented investors.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
